Wednesday, October 22, 2008

U.S. FDA Approves Prezista Once-Daily as Part of Combination Therapy for Treatment-Naive Adults with HIV-1

The FDA has granted PREZISTA (darunavir) tablets, a protease inhibitor, approval for an expanded indication for once-daily dosing as part of HIV combination therapy in treatment-naive adults (those who have never taken HIV medication before). The FDA also granted traditional (full) approval to PREZISTA as twice-daily for use in treatment-experienced adult patients.

The details can be read here.

1 comment:

Anonymous said...

This is a good step which FDA had taken for an approval of HIV combination therapy in the treatment. i know one more resource about the same which provides medicines for treatment like generic flomax